Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours

Sandra L. Preston, Peter J. Piliero, John A. Bilello, Daniel S. Stein, William T. Symonds, George L. Drusano
Sandra L. Preston
1Division of Clinical Pharmacology, Clinical Research Initiative, Albany Medical College, Albany, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Piliero
1Division of Clinical Pharmacology, Clinical Research Initiative, Albany Medical College, Albany, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Bilello
2Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel S. Stein
2Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William T. Symonds
2Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George L. Drusano
1Division of Clinical Pharmacology, Clinical Research Initiative, Albany Medical College, Albany, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: GLDRUSANO@AOL.COM
DOI: 10.1128/AAC.47.11.3393-3399.2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    The effect of amprenavir on HIVIIIB replication is shown when continuous-infusion (▴), BID (•), TID (+), and no-drug (▪) regimens are followed.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    The effect of amprenavir on HIV suppression as a function of time > EC95 is shown for continuous-infusion, BID, and TID regimens.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    The plot of observed versus predicted amprenavir concentrations in plasma after population pharmacokinetic modeling and MAP-Bayes estimation is shown.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    (A) The target attainment rate for a given EC50 for amprenavir and ritonavir at doses of 600 and 100 mg, respectively, is shown with a target of more than four times the EC50. (B) The target attainment rate for a given EC50 for amprenavir and ritonavir at does of 600 and 100 mg, respectively, is shown with a target Cmin/EC50 ratio of 5.

Tables

  • Figures
  • TABLE 1.

    Characteristics of study group

    CharacteristicValue for:
    Participants in pharmacokinetics analysis (n = 12)Trial participants (n = 13a)
    Gender
        Male99
        Female34
    Race
        Caucasian55
        African-American45
        Hispanic33
    Age (yr)
        Mean38.237.3
        Range31.1-47.725.9-47.7
    Wt (kg)
        Mean83.981.1
        Range66.4-106.950-106.9
    Baseline CD4-cell count (no. of cells/mm3)
        Mean292281
        Range42-61842-618
    Baseline viral load (no. of log10 copies/ml)
        Mean4.244.25
        Range3.44-5.653.44-5.65
    • ↵ a One patient was excluded from the pharmacokinetic analysis.

  • TABLE 2.

    Pharmacokinetic parametersa

    Determinationkel (h−1)Ka (h−1)V1 (liter)Kcp (h−1)Kpc (h−1)Time lag (h)
    Mean0.17916.78100.65.04912.420.616
    Median0.1808.55092.500.7200.3860.470
    SD0.061415.4846.128.96717.550.300
    • ↵ a k el, elimination rate constant; Ka, absorption rate constant; V1, volume of distribution in the central compartment; Kcp, intercompartmental rate constant from the central to the peripheral compartment; Kpc, intercompartmental rate constant from the peripheral to the central compartment; time lag, lag time to absorption.

PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours
Sandra L. Preston, Peter J. Piliero, John A. Bilello, Daniel S. Stein, William T. Symonds, George L. Drusano
Antimicrobial Agents and Chemotherapy Oct 2003, 47 (11) 3393-3399; DOI: 10.1128/AAC.47.11.3393-3399.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours
Sandra L. Preston, Peter J. Piliero, John A. Bilello, Daniel S. Stein, William T. Symonds, George L. Drusano
Antimicrobial Agents and Chemotherapy Oct 2003, 47 (11) 3393-3399; DOI: 10.1128/AAC.47.11.3393-3399.2003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-HIV Agents
antiviral agents
ritonavir
Sulfonamides

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596